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responsibility of XAbstract A rapid and sensitive ﬂow-injection chemiluminescence (CL) method for the determina-
tion of glipizide was developed on the basis of ﬁnding that glipizide can enhance the CL intensity of
the luminol–K3Fe(CN)6 system. In optimum condition, the increased CL intensity was directly
proportional to the concentration of glipizide in the range from 4.0 108 g/mL to 1.0 106 g/
mL and the detection limit was 1.0 108 g/mL glipizide. The relative standard deviation (RSD) of
the developed method was 2.1% with 11 repeated measurements of 1.0 107 g/mL glipizide. The
developed method has been successfully applied to the analysis of glipizide in its pharmaceutical
preparations.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Glipizide (GP), 1-cyclohexyl-3-[[p-[2-(5-methylpyrazine-carboxami-
do)ethyl]-phenyl]-sulfonyl]urea (as shown in Scheme 1), is a second
generation sulfonylurea hypoglycemic agent and is typically used
in the treatment of non-insulin dependent diabetes mellitus [1,2],
which lowers the blood glucose level in humans by stimulating the
release of insulin from the pancreas and helping the body to useersity. Production and hosting by E
.002
29 82655399.
u.cn (Y.-H. Tang).
i’an Jiaotong University.insulin efﬁciently [3]. Because its effect is indeed quick and well
tolerated, more importantly for a long-term use, GP has been
widely used, as an ideal anti-diabetic drug with the more
commonly-known name Glucotrol, in Europe as well as other
regions worldwide [4]. Therefore, it is quite necessary to develop a
new method for the analysis of GP.
In the past few years, several methods were reported for the
determination of GP, which involved different high perfor-
mance liquid chromatographies (HPLCs) [5–13], liquid
chromatography–mass spectrometry (LC–MS) [14–17], ultra-
violet spectrophotometry [18], thin-layer chromatography
(TLC) [19] and an electrochemical method [20]. Most of these
methods are tedious, inconvenient and suffer from low
sensitivity and narrow linear range.
Recently, extremely sensitive analytical techniques based on
chemiluminescence (CL) systems (such as NBS–H2O2–lsevier B.V. All rights reserved.
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Fig. 1 Schematic diagram of the ﬂow system for the determina-
tion of GP. A: luminol; B: NaOH; C: K3[Fe(CN)6]; D: sample/
blank; P1, P2: peristaltic pumps; V: six-way valve; E: ﬂow cell; W:
waste; NHV: negative high voltage; PMT: photomultiplier; PC:
computer; AMP: ampliﬁer.
X. Chen et al.128nitrofurazone, KMnO4–Na2SO3–atenolol, luminol–potassium
peroxydisulfate–bisphenol, etc. [21,22]), have been paid con-
siderable attention, which had been applied in determining
trace and ultra-trace concentrations of inorganic and organic
species (like drugs or pesticides) in a variety of industrial,
clinical and environmental matrices [23]. The CL method had
the advantages such as high sensitivity, relatively inexpensive
apparatus, short analysis time, wide working range, low
detection limit and no background scattering light interfer-
ence. Coupled with ﬂow injection analysis (FIA), the reprodu-
cibility and selectivity of CL analysis can be improved
signiﬁcantly. However, up to now, there is no report on the
use of FI-CL method for determination of GP in pharmaceu-
tical preparations. In this work, it was found that GP could
obviously enhance the CL of the luminol–K3Fe(CN)6 reaction
in NaOH solution and the enhanced CL was proportional to
the concentration of GP. So, a new ﬂow-injection CL method
was proposed and the mechanism of luminol–K3Fe(CN)6–GP
was also discussed brieﬂy.Fig. 2 Chemiluminescence kinetic curves: a, 8.0 105 M lumi-
nolþ6.0 105 M K3Fe(CN)6; b, 8.0 105 M luminolþ
6.0 105 M K3Fe(CN)6þ1.0 107 g/mL GP.2. Materials and methods
2.1. Reagents and solutions
All solutions were prepared from analytical reagent grade
chemicals combined with double distilled water.
A stock solution of GP (1.0 103 g/mL) was prepared by
dissolving 0.1000 g of GP (National Institute of Pharmaceu-
tical and Biological Authentication of China, Xi’an, China) in
alcohol and then diluting to 100 mL.
Luminol stock solution (1.0 102 M) was obtained by
dissolving 0.1771 g of luminol (Aldrich, Sigma-Aldrich
Quımica) in 10 mL 0.1 M NaOH and diluting to 100 mL
with water.
Potassium ferricyanide stock (1.0 102 M) was prepared
by dissolving 0.1150 g K3Fe(CN)6 (Xi’an Chemical Reagent
Factory, Xi’an, China) in distilled water and then diluting to
50 mL.
The stock solutions were stored at 41C in a refrigerator and
protected from light. The working solutions were prepared by
diluting stock solutions freshly into appropriate concentration
with water before being used.
2.2. Apparatus and procedures
The CL measurement was conducted on an IFFM-E ﬂow
injection CL analyzer (Xi’an Remax Electronic Science-Tech.
Co. Ltd., Xi’an, China), which includes a model IFFM-E ﬂow
injection system and a model IFFS-A luminometer. A sche-
matic representation of the proposed FI-CL system for the
detection of GP is illustrated in Fig. 1. Two peristaltic pumps,
labeled as P1 and P2, were used to deliver the respective
components to the ﬂow cell at a ﬂow rate of 2.65 mL/min. Thetubes A, B, C and D were used to deliver luminol solution,
NaOH solution, K3Fe(CN)6 solution and sample or blank
solution, respectively. Luminol solution was premixed with
potassium ferricyanide. Then, a certain amount of GP sample
was delivered into the emerging stream through the six-way
injection valve. The light output from the CL reaction was
detected and ampliﬁed with a photomultiplier tube and
luminometer. Data acquisition and processing were performed
using the IFFM-E software running under Windows XP. The
determination of GP was accomplished based on the increase
in the CL intensity, calculated as DI¼II0, where I denotes
the CL signal in the presence of GP and I0 is the CL intensity
corresponding to baseline.3. Results and discussion
3.1. Kinetic characteristic of the CL reaction
The kinetic curves of the CL reaction of luminol–K3Fe(CN)6–
GP system were taken on an IFFS-A multipurpose chemilu-
minescence detector (shown in Fig. 2). It could be seen that the
oxidation of luminol with K3Fe(CN)6 was comparatively fast
(2–3 s) and the CL intensity was relatively strong. The CL
signal (3200) in the presence of GP (1.0 107 g/mL) is
stronger than that (5350) in the absence of GP. The results
indicated that GP could sensitize the CL emission of luminol–
K3Fe(CN)6 system signiﬁcantly.
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Fig. 4 Effect of K3Fe(CN)6 concentration on CL intensity:
1.0 107 g/mL glipizide and 8.0 105 M luminol
(0.1 M NaOH).
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Fig. 5 Effect of NaOH concentration on CL intensity:
1.0 107 g/mL glipizide; 6.0 105 M K3Fe(CN)6; and
8.0 105 M luminol.
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The characteristics of several oxidants, including KMnO4,
K3Fe(CN)6, KIO4 and H2O2 of the same concentration
reacting with luminol CL systems in the presence of GP, were
evaluated. It was found that GP had more effective enhance-
ment in luminol–K3Fe(CN)6 system, compared with other
systems. Therefore, K3Fe(CN)6 was selected as an oxidant for
the subsequent study.
3.3. Effect of sample injection sequences
In this work, different injection sequences were tested to
optimize conditions. The strongest relative CL intensity was
found when K3Fe(CN)6 solution was premixed with luminol
and then with sample solution (as described in Fig. 1).
3.4. Optimization of experimental conditions
A series of experiments had been performed for optimizing the
chemical and instrumental parameters affecting the analytical
response, which included the component concentration, ﬂow rate,
the length of mixing tube, etc. 1.0 107 g/mL standard solution
of GP was applied to optimizing the experimental conditions.
3.4.1. Effect of chemical variables
The chemical variables that need to be assessed include
luminol, potassium ferricyanide and the medium. The effect
of luminol concentration (the medium was 0.1 M NaOH) was
investigated in the range of 8 106–2 104 M. As shown in
Fig. 3, increasing the luminol resulted in a sharp increase in
the relative CL signal up to 8 105 M; after that, 1 106 g/
mL glipizide could not be detected (the CL signal had reached
beyond the maximum system detection) and S/N decreased
although CL still increased. Considering the stability of the
CL signal, a luminol concentration of 8 105 M was selected
for the subsequent experiment.
The dependence of the increased CL intensity (DI) on the
concentrations of potassium ferricyanide was examined in the
range from 1.0 106 M to 1.0 103 M. The result related to
1.0 105 M–10 105 M is shown in Fig. 4. A general
improvement in the CL intensity sharply increases with an
increase of the concentration of potassium ferricyanide from
1.0 105 M to 4.0 105 M, and then slowly increases.
6.0 105 M potassium ferricyanide was selected to further
study since a higher signal to noise ratio was obtained in this
concentration solution.0
2000
4000
6000
8000
10000
12000
0 5 10 15 20 25
Concentration of luminol (10-5M)
ΔI
 (m
V)
 
Fig. 3 Effect of luminol concentration on CL intensity:
1.0 107 g/mL glipizide; 6.0 105 M K3Fe(CN)6 and
0.1 M NaOH.The CL signal was tested in several alkaline solutions,
which included NaOH, Na2CO3, NaHCO3, Na3PO4 and
Na2HPO4. We observed that the CL signal was stronger when
adding appropriate concentration of NaOH in the reaction
system. In this work, over the range 0.005–0.2 M, the effect of
the concentration of NaOH was studied and the results are
shown in Fig. 5. Maximum CL response was obtained at a
NaOH concentration of 0.1 M, over which the relative CL
intensity signal did not increase remarkably any more. So,
0.1 M NaOH was regarded as the optimized working concen-
tration for the subsequent work.3.4.2. Effect of instrumental parameters
The effect of ﬂow rate on the CL response was calibrated in
terms of sensitivity, reagent consumption and speed. Flow rate
V0 was studied over the range 1.55–4.50 mL/min in each
stream. The results showed that the CL response continued
to increase with increasing ﬂow rate up to 2.65 mL/min, at
which maximum CL intensity was observed, and then began
to drop. Thus, a ﬂow rate of 2.65 mL/min was chosen as the
suitable rate with a steady baseline and reproducible peak
height.
The length of the mixing tubing (L0) was also adjusted to
yield maximum light emission in the cell. Because CL reaction
is very fast, if the length of mixing tubing to the ﬂow cell is too
long or too short, the CL signal cannot be detected. In this
work, the effect of L0 was investigated over the range from 3
to 15 cm. It was found that a 10 cm mixing tubing afforded the
best results with good reproducibility and sensitivity, which
was selected for further work.
To sum up, the optimized conditions consisted of luminol
(8 105 M) in NaOH (0.1 M) as the stream with a ﬂow rate
X. Chen et al.130of 2.65 mL/min and potassium ferricyanide (6.0 105 M)
introduced to the carrier by a six-way valve selected for the
purpose of optimization.
3.5. Analytical performance—calibration curve, detection
limit and precision
A series of working standard solutions of GP with different
concentrations (1.0 108 g/mL–1.0 104 g/mL) were pre-
pared by diluting freshly respective stock standard solutions
with water. Under the selected experimental conditions
described above, DI, the difference in CL intensity in the
absence and presence of GP, possessed a linear relationship
with GP concentration ranging from 4.0 108 g/mL to
1.0 106 g/mL. The linear regression equation was expressed
as DI¼19.738cþ1102.9 (r¼0.9901, n¼5). The detection limit
(3s) of the method was estimated to be 1.0 108 g/mL and
the relative standard deviation (RSD) for determination of
1.0 107 g/mL GP was 2.1% (n¼11), which was indicative
of repeatability and reproducibility of the assay.
3.6. Interference
In order to assess the selectivity of the developed CL method,
varying amounts of possible interfering substances were added
to the determination of a standard GP solution (1.0 107 g/
mL). The obtained signals were tested against a pure solution
of GP at the same concentration. The tolerance of foreign
species was taken as the largest concentration yielding a
relative error less than 5% in CL signal. In all the mixed
media, the determined GP concentration was in good agree-
ment with that in the pure GP solution. The above results
indicated that the common accessories found in the pharma-
ceutical preparations, including lactose, starch, glucose, sac-
charin, sucrose and magnesium stearate, had no obvious
effects on the determination of GP. And the existence of
1000-fold Ca2þ, Mg2þ, Kþ, SO4
2, NO3
; 100-fold Al3þ, Zn2þ,
Ni2þ and 50-fold CO3
2, Cl did not interfere with the
determination.
3.7. Stability
It was found that the response factors of standard solution
were unchanged for 2 weeks at least. Thus, the solutions can
be used within this period without affecting the results.
Moreover, different temperatures of the CL reaction were
also studied and the results showed that it had remarkable
effect on CL emission signal; in this study, constant tempera-
ture of 25 1C was chosen as the suitable work temperature.
3.8. Application
The proposed FI-CL method was successfully applied to the
analysis of GP commercial pharmaceutical tablets (1009141,
5 mg per tablet, Jiangsu Pingguang Pharmaceutical Group,
Co., Ltd., Jiangsu, China). The sample solution was prepared
by dissolving a quantity of sample equivalent to one tablet
from 10 tablets and by sonication with appropriate volume of
alcohol for 20 min to aid its dissolution. The dissolved sample
was ﬁltrated with Whatman No. I ﬁlter paper and diluted with
distilled water to 100 mL. We diluted the sample solution tothe linear range for analysis. The result obtained (4.7 mg per
tablet, n¼5) is in good agreement with the Chinese pharma-
copoeia reference method (4.8 mg per tablet, n¼5) and the
nominal content of GP (5.0 mg per tablet), the RSD being less
than 2%. The recoveries were determined by adding 3 GP
solutions (1.5 107, 3.0 107, 5.0 107 g/mL) respectively
to the pharmaceutical preparation (2.0 107 g/mL). The
determination results (n¼9) were 3.46 107, 4.94 107,
6.95 107 g/mL, correspondingly, the average recovery being
98.1%, which was in the acceptable range.
3.9. Discussion of possible CL mechanism
In order to obtain the CL reaction mechanism, the ﬂuores-
cence spectra of luminol, luminol–K3Fe(CN)6, and luminol–
K3Fe(CN)6–GP reaction were scanned in the range of 280–
650 nm, using an RF 5301 ﬂuorescence spectrophotometer. It
had been reported that 3-aminophthalate ion (3-AP), an
oxidized product of luminol, peaking at 425 nm was known
as the emitter in the luminol–K3Fe(CN)6 system [24]. The
results obtained were all found to have the same maximum
emission appearing at 425 nm; the luminophor was conﬁrmed
to be 3-AP. This indicated that the luminant in the luminol–
K3Fe(CN)6–GP system was still 3-AP.
On the other hand, when GP standard solution, luminol
solution and K3Fe(CN)6 solution were purged with nitrogen
for 5 min and the dissolved oxygen was removed from all
solutions, it was found that the CL intensity decreased by
about 30%. The result indicated that the dissolved oxygen is
required in the CL reaction.
The superoxide radical had been conﬁrmed to oxidize
luminol to produce CL in alkaline solution [25]. The increas-
ing agents could increase dissolved oxygen to intermediate
superoxide radical in alkaline solution. The produced super-
oxide radical reacts with luminol to yield an unstable endoper-
oxide leading to an excited aminophalate. The CL reaction of
luminol with superoxide radical can be catalyzed by potassium
ferricyanide in alkaline solution.
Based on the discussion described above, the possible CL
reaction mechanism was considered as follows:
luminolþK3FeðCNÞ6-3-aminophthalate ionn ð3-APnÞ
3-APn-3-APþ hn lmax ¼ 425 nmð Þ
GPþ dissolved oxygenþNaOH-superoxide radical
þ other reaction product
Superoxide radicalþ luminolþK3FeðCNÞ6-3-APn
3-APn-3-APþ hn ðlmax ¼ 425 nmÞ
4. Conclusion
A sensitive FI-CL method for the determination of anti-
diabetic drug—GP based on luminol and potassium ferricya-
nide in NaOH was proposed for the ﬁrst time in the present
work. It had been proved that this method is sensitive, simple
and rapid to analyze GP in pharmaceutical preparation based
on its sensitizing effect. The result obtained was in reasonable
agreement with that achievable by the Chinese pharmacopoeia
Luminol–K3Fe(CN)6 chemiluminescence system for the determination of glipizide 131method. If combined with separation techniques, the system
may be adopted to detect GP in other samples.
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